This brand name is authorized in Finland
The drug NEOPROCT contains a combination of these active pharmaceutical ingredients (APIs):
1
Fluocortolone
UNII 9J8AL6K50Q - FLUOCORTOLONE PIVALATE
|
Fluocortolone pivalate inhibits inflammatory and allergic skin reactions, and alleviates subjective complaints such as pruritus, smarting, and pain. The substance reduces dilatation of the capillaries, oedema of the interstitial cells and infiltration of the tissues. Capillary multiplication is inhibited. |
2
Lidocaine
UNII V13007Z41A - LIDOCAINE HYDROCHLORIDE
|
Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
C05AA08 | Fluocortolone | C Cardiovascular system → C05 Vasoprotectives → C05A Agents for treatment of hemorrhoids and anal fissures for topical use → C05AA Corticosteroids |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: FI | Lรครคkealan turvallisuus- ja kehittรคmiskeskus | Identifier(s): 155333, 155341, 155457 |
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.